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Abstract
Facioscapulohumeral muscular dystrophy(FSHD) is a disorder character-
ized by muscle weakness and wasting (atrophy). This disease is typically
inherited as autosomal dominant and has a complex genetic and epigenetic
etiology. Our collaborator had differentiated healthy human pluripotent stem
cells(iPSC) into skeletal muscles and exploited ISO-Seq to explore cell gene
expression and transcript alternative splicing usage profile during 8 differen-
tiation stages. Later, stage specific gene differential expression, transcript
alternative splicing, gene ontology and novel gene/transcript were analysed
to characterize the feature of each stage during the differentiation. In terms
of expressed genes with more than or equal to 5 transcripts, each stage had
shown their own stage specific features. About transcripts, iPS, S1, ADM.D0,
ADM.D4 have about 30% to 40% more total transcripts than the rest 4 stages.
4 kinds of alternative splicing events are generally distributed and S2 stage
has the least alternative splicing events potentially due to technical reasons.
As for gene differential expressions, ADM.D4 has considerable amount of dif-
ferential expressed genes with 5 other stages and it has minor difference with
ISM.D4 and S3 stages(they are all myotubes cells). The gene ontology anal-
ysis is performed according to the results of previous step, stage specific GO
terms are revealed.
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1 Introduction
1.1 Induced pluripotent Stem Cells
Under certain conditions, adult cells can be genetically reprogrammed into induced
pluripotent stem cells(iPSCs). Due to their remarkably similarity to embryonic
stem cells in many key aspects, iPSCs have the potential to become effective tools
to understand and model diseases and deliver cell-replacement therapy to support
regenerative medicine [1].
Facioscapulohumeral muscular dystrophy is typically inherited as autosomal
dominant and has a complex genetic and epigenetic etiology [2], characterized by
muscle weakness and wasting [3]. In our study, human iPS cells were differentiates
into muscle cells, 8 samples from 3 cell lines are collected. In the first cell line, iPS
cells were obtained at day 0. After 5 days in S1 medium, iPS cells were developped
into skeletal muscle progenitor cells(stage S1), then 4 days in S2 medium, skeletal
muscle myoblasts(S2 stage) were induced. At day 7, S2 stage cells differentiated as
myotubes(S3 stage). Additionally, iPS derived secondary myoblasts(ISM.D0) were
differentiated into myotubes(ISM.D4) 4 days later. There is also another parental
adult line, adult myoblasts(ADM.D0) differentiated into adult myotubes(ADM.D4)
at day 4. Generally speaking we have 3 cell lines: iPS to S1 to S2 to S3; ISM.D0 to
ISM.D4 and ADM.D0 to ADM.D4
1.2 Iso-Seq analysis of RNA expression
The Pacific Biosciences(PacBio) transcript Sequencing(ISO-Seq) method employs
long read to sequence transcript transcripts from the 5‘ end to their poly-A tails [4].
This new technique can reduce the effort and error during reconstructing and in-
ferencing short reads. In preivious researches, ISO-Seq has been used to analyze
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full-length splice transcripts in human organs and embryonic stem cells, indicating
that even in highly characterized transcriptome like human, the identification of
genes and splice transcripts is far from complete [5]. Here, ISO-Seq was performed
to characterize the stage specific RNA expression profile. The sequencing work
was conducted by Umass Medical Sequencing Core. They had also classified and
clustered the circular consensus(CCS) reads following the PacBio ISO-Seq analysis
application work flow [6] and produced high quality transcript sequence files. Ex-
cept for iPS stage, the sequencing data of each stage consists of 2 parts: 1-3kb, over
3kb. The over 3kb part data of S2 stage was dropped because of containing lots
of mitochondrial sequences and caused much trouble during the ISO-Seq analyze
step(Figure 1 ). Sequence data of iPS stage is mainly distributed in 1-3kb part, this
could be resulted by Iso-Seq technique or sample preparation reasons. During our
analysis, the 1-3kb and over 3kb data were first combined into one file, then I aligned
the transcripts to reference genome using GMAP/GSNAP(Genomic Mapping and
Alignment Program for mRNA and EST Sequences, and Genomic Short-read Nu-
cleotide Alignment Program) [7]. According to the sam file alignment, transcript
sequences were collapsed into final set of unique, full-length, high-quality transcripts
following ToFU(transcript transcripts: Full-length and Unassembled) [8] pipeline.
After that, basic statistical summary of the data was made by Python, alterna-
tive splicing events distribution was counted by SpliceGrapher [9]. Gene differential
expression analysis performed by R package edgeR [10] revealed some relations be-
tween stages, gene ontology analysis of differential expressed genes were performed
by R package clusterProfiler [11]. Finally novel genes and novel transcripts were
obtained by comparing with reference genome using IGV [12].
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 1: Read length Distribution.
3
2 ISO-Seq analysis of gene expression during iPSC
induction and differentiation
2.1 Pipeline
Figure 2: Pipeline of the analysis
The high quality transcript sequence data was obtained from Umass Medical Se-
quencing Core, I aligned the fasta file to reference genome using GMAP(parameter
setting: −f samse − n 0 − t 16 − −cross − species − −max − intronlength −
ends 200000 − z sense force). Cupcake Tofu collapsed all redundant reads into
unique transcripts and annotated all transcripts according to reference genome. Un-
matched isforms are considered as possible novel transcripts, matched transcripts
are used to perform gene expression analysis and functional analysis.
Our data was provided by researchers from Umass medical. They classified and
clustered the raw data from Iso-Seq platform and generated high quality transcript
sequence data. In the high quality data, each sequence is assumed to be full-length,
supported by 2 or more full length reads and have a predicted accuracy over 99%
by default. Because of the natural 5‘ degradation in rranscripts and clustering algo-
rithm trade off between sensitivity and specificity, it is possible that some identical
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or redundant transcripts still exist [8]. I used Cupcake ToFU to collapse redundant
transcripts to obtain unique transcripts. With errors and redundant eliminated,
read numbers in our data also dropped(Table1).
Then every unique transcript was annotated using Genecode v19 human Genome
data. Annotated transcripts are used to explore differential expressed genes be-
tween stages using R package edgeR. Functional analysis conducted by R package
clusterProfiler also revealed the functions and pathways related to these differential
expressed genes. transcripts that can not be annotated are considered as possible
novel gene or transcripts, part of them were validated by IGV visualization.
step iPS S1 S2 S3 ISM.D0 ISM.D4 ADM.D0 ADM.D4
high quality data 28282 34282 17654 19942 17174 17847 42037 31022
unique transcripts 23199 27497 14580 16564 14360 14895 27528 25422
matched transcripts 22450 26866 14292 16387 14197 14670 26677 24667
unmatched transcripts 749 631 288 177 163 225 851 755
Table 1: Read numbers during each step
The high quality data still contains some redundant transcript. After collapsing,
redundant is eliminated, unique transcripts are obtained, which means every read
is a unique transcript.
2.2 Gene annotation and transcript analysis
High quality transcripts were aligned to Gencode v19 human genome using GMAP
[7]. Since Clustering algorithm would balance its sensitivity and specificity, it is
possible that some high quality sequences represent identical or redundant tran-
scripts, Cupcake ToFU pipeline [8] was used to collapse identical transcripts and
obtain final set of unique, full-length, high quality transcripts, after this step multi-
5
ple reads could be collapsed into one transcript. The annotation files were produced
by Cupcake Annotation comparing against Genecode v19 gene model.
2.2.1 Transcript counts distribution
R was used for the statistical analysis and plotting.From the bar plot, ISM.D0 stages
has the lowest number of transcripts 14197, which is similar to ISM.D4, S2 and S3
stage, but much lower than that of other stages. S1 stages has the highest number
of transcripts, 26866. There is no significant a distinct gap between number of
transcripts during ISM differentiation, and adult myoblast differentiation. Although
over 3kb part is missing in S2 stage, significant decreasing can be observed during
mononucleated myocytes differentiation(S1 to S3).
Figure 3: transcript numbers distribution
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2.2.2 Alternative splicing distribution
Figure 4: Alternative Splicing events distribution
4 kinds of alternative splicing events are counted in our study: Alt3, 3‘ alternative
splicing; Alt5, 5‘ alternative splicing; ES, exon skipping; IR, intron retention
With alternative splicing(AS), a gene can be transcripted into different transcripts,
with SpliceGrapher, 4 types of AS events are counted in our data: Alt5: 5′ alterna-
tive splicing; Alt3: 3′ alternative splicing; ES: exon skipping; IR: intron retention.
From the figure above, the distribution of AS events are pretty average across dif-
ferent stages(S2 stage contains less AS events might be resulted from its missing
data). 2 ISM stages are extremely similar to each other. For each stages, their
genes with most AS events are also genes with most transcripts, detail informa-
tion could be found in table 4 to table 11. However, the alternative splicing event
numbers are significantly smaller than transcript numbers(Figure 1), since I didn’t
compare our data against alternative splicing reference data, much alternative splic-
ing information can not be obtained by comparing against reference genome, the
result is reasonable.
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2.2.3 Gene counts distribution
Since Cupcake Annotation already mapped every transcript to a reference transcript
and reference gene, the gene counts distribution can be obtained directly(Figure 5).
Comparing to total transcript counts distribution(Figure 3), over 80% of transcripts
are generated by about 50% genes, these genes are potentially to play an impor-
tant role in stage-wise biological functions. S1 and ADM.D0 stage has the largest
expressed gene numbers. Significant differences can be observed between secondary
myoblasts differentiation and adult myoblasts differentiation processes(ISM.D0 to
ISM.D4 and ADM.D0 to ADM.D4), while both secondary myoblasts differentia-
tion and adult myoblasts differentiation didn’t show much gene number differences
within the process. In total, 1966 genes are expressed in all 8 stages.
(a) (b)
Figure 5: Number of genes distribution during different stages.
(a)genes with 1 transcript. (b) genes with more than 1 transcript. Most transcripts
are expressed by a small number of genes.
After the collapse step in Cupcake ToFU, multiple reads could be collapsed into
one transcript, here we didn’t consider about the read number for every gene, simply
regard every observed gene as expressed, and counted shared gene numbers between
8
stages. From the 2 tables below(Table 2 and Table 3), the absolute number of share
genes in all 8 stages data are quite similar with each other. The proportion of
shared genes among every 2 stage group is about 50% (proportion of shared genes
= Intersect(genes in stage A, genes in stage B)/Union(genes in stage A, genes in
stage B)). Theoretically, the gene number and transcript numbers may be strongly
influenced by the total number of reads sequenced even we have obtained the unique
transcript data, which means the gene numbers expressed in samples may be differ
due to experiment technical reasons .
But when I narrow the range of genes, things changed a little bit. When I
only compare genes with over 1 transcript, the proportion of share genes dropped
significantly(Table 3), when genes with over or equal to 5 transcripts were compared,
the 8 stages showed their stage features(Table 4). The proportion of shared genes
in genes with over of equal to 5 transcripts is relatively small, which suggest that
most of the genes are related to stage wise functions.
stage iPS S1 S2 S3 ISM.D0 ISM.D4 ADM.D0
S1 6009
S2 4834 5086
S3 4845 5143 4633
ISM.D0 4544 4820 4551 4504
ISM.D4 4635 4823 4587 4819 4504
ADM.D0 5232 5790 4687 4971 4549 4695
ADM.D4 5031 5511 4548 4912 4415 4708 5897
Table 2: Intersection of expressed genes across different stages(absolute value)
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stage iPS S1 S2 S3 ISM.D0 ISM.D4 ADM.D0
S1 54.41%
S2 46.58% 51.15%
S3 46.33% 50.92% 48.62%
ISM.D0 44.86% 49.31% 50.53% 49.03%
ISM.D4 44.56% 48.43% 49.13% 51.49% 50.23%
ADM.D0 46.19% 51.18% 45.55% 49.66% 45.32% 48.09%
ADM.D4 45.55% 52.03% 45.88% 48.25% 45.54% 46.43% 54.88%
Table 3: Intersection of expressed genes across different stages(proportion)
stage iPS S1 S2 S3 ISM.D0 ISM.D4 ADM.D0
S1 46.99%
S2 34.58% 38.56%
S3 33.40% 38.62% 35.90%
ISM.D0 33.36% 36.74% 38.39% 37.64%
ISM.D4 31.98% 35.21% 37.07% 41.72% 39.74%
ADM.D0 37.11% 45.31% 33.28% 37.94% 34.80% 34.42%
ADM.D4 35.50% 42.57% 33.39% 40.12% 34.15% 38.05% 49.66%
Table 4: Intersection of expressed genes(>1 transcript) across different
stages(proportion)
10
stage iPS S1 S2 S3 ISM.D0 ISM.D4 ADM.D0
S1 32.36%
S2 20.98% 19.80%
S3 18.01% 21.02% 24.67%
ISM.D0 19.75% 22.12% 30.92% 29.73%
ISM.D4 17.78% 18.27% 26.47% 35.23% 30.56%
ADM.D0 20.49% 28.76% 15.47% 22.37% 19.86% 17.62%
ADM.D4 20.60% 26.19% 15.93% 25.60% 19.63% 23.04% 36.96%
Table 5: Intersection of expressed genes(>=5 transcripts) across different
stages(proportion)
The transcript numbers could vary between different genes. In the same stage,
some genes might contains hundreds of transcripts, while some only contain 1(Figure
5)Genes with extremely large transcript numbers must be closely related to stage-
wise functions even though gene numbers could be influenced by other factors. Top
10 genes ranked by transcript numbers of each stage are listed below. In generally,
some genes are highly expressed in many cell stages like collagen genes, hetero-
geneous nuclear ribonucleoprotein K gene, myosin genes, insulin-like growth factor
gene, pyruvate kinase gene and titin genes, etc. Some genes are only observed highly
expressed in certain stages, like TERF1(iPS), CSDE1(S1), TUBB(S2), SPARC(S3),
ANXA2(ISM.D0), MEG3(ISM.D4), SULF1(ADM.D0), they obviously have distinct
stage feature.
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gene transcripts Description
TERF1 29 telomeric repeat binding factor 1
JARID2 27 jumonji, AT rich interactive domain 2
NAP1L1 25 nucleosome assembly protein 1-like 1
KPNB1 24 karyopherin (importin) beta 1
SNHG14 24 small nucleolar RNA host gene 14
PABPC1 23 poly(A) binding protein, cytoplasmic 1
HNRNPK 22 heterogeneous nuclear ribonucleoprotein K
HSP90AA1 21 heat shock protein 90kDa alpha (cytosolic), class A member 1
HNRNPC 20 heterogeneous nuclear ribonucleoprotein C (C1/C2)
BPTF 20 bromodomain PHD finger transcription factor
Table 6: List of top ranked genes in iPS stage
gene transcripts Description
COL11A1 40 collagen, type XI, alpha 1
COL1A2 36 collagen, type I, alpha 2
CSDE1 32 cold shock domain containing E1, RNA-binding
HMGA2 30 high mobility group AT-hook 2
HNRNPK 30 heterogeneous nuclear ribonucleoprotein K
KPNB1 29 karyopherin (importin) beta 1
MYH9 28 myosin, heavy chain 9, non-muscle
PABPC1 28 poly(A) binding protein, cytoplasmic 1
SEC31A 25 SEC31 homolog A (S. cerevisiae)
SEPT11 24 septin 11
Table 7: List of top ranked genes in S1 stage
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gene transcripts Description
ACTG1 17 actin, gamma 1
MAP1B 16 microtubule-associated protein 1B
TUBB 14 tubulin, beta class I
HSP90AA1 14 heat shock protein 90kDa alpha (cytosolic), class A member 1
IGF2 14 insulin-like growth factor 2
HSPD1 14 heat shock 60kDa protein 1
HNRNPK 13 heterogeneous nuclear ribonucleoprotein K
PKM 13 pyruvate kinase, muscle
HNRNPA2B1 13 heterogeneous nuclear ribonucleoprotein A2/B1
MEG3 13 maternally expressed 3 (non-protein coding)
Table 8: List of top ranked genes in S2 stage
gene transcripts Description
COL3A1 70 collagen, type III, alpha 1
COL1A2 63 collagen, type I, alpha 2
COL1A1 43 collagen, type I, alpha 1
MYH3 33 myosin, heavy chain 3, skeletal muscle, embryonic
H19 32 H19, imprinted maternally expressed transcript (non-protein coding)
COL5A2 30 collagen, type V, alpha 2
SPARC 28 secreted protein, acidic, cysteine-rich (osteonectin)
COL4A2 28 collagen, type VI, alpha 2
COL4A1 27 collagen, type VI, alpha 1
IGF2 26 insulin-like growth factor 2
Table 9: List of top ranked genes in S3 stage
gene transcripts Description
ANXA2 58 annexin A2
COL1A1 53 collagen, type I, alpha 1
H19 48 H19, imprinted maternally expressed transcript (non-protein coding)
ACTG1 46 actin, gamma 1
PKM 46 pyruvate kinase, muscle
COL3A1 45 collagen, type III, alpha 1
IGF2 44 insulin-like growth factor 2 (somatomedin A)
TPM1 44 tropomyosin 1 (alpha)
HNRNPK 42 heterogeneous nuclear ribonucleoprotein K
ITGB1 42 integrin, beta 1
Table 10: List of top ranked genes in ISM.D0 stage
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gene transcripts Description
TTN 38 titin
COL1A1 35 collagen, type I, alpha 1
MYH3 33 myosin, heavy chain 3, skeletal muscle, embryonic
COL3A1 32 collagen, type III, alpha 1
IGF2 28 insulin-like growth factor 2 (somatomedin A)
COL1A2 26 collagen, type I, alpha 2
MEG3 26 maternally expressed 3 (non-protein coding)
COL4A1 22 collagen, type IV, alpha 1
FN1 21 fibronectin 1
PALLD 20 palladin, cytoskeletal associated protein
Table 11: List of top ranked genes in ISM.D4 stage
gene transcripts Description
TTN 294 titin
FN1 262 fibronectin 1
COL1A2 131 collagen, type I, alpha 2
PALLD 95 palladin, cytoskeletal associated protein
DST 92 dystonin
COL1A1 85 collagen, type I, alpha 1
NEB 80 nebulin
SULF1 76 sulfatase 1
COL3A1 75 collagen, type III, alpha 1
MEF2C 75 myocyte enhancer factor 2C
Table 12: List of top ranked genes in ADM.D0 stage
gene transcripts Description
TTN 259 titin
NEB 74 nebulin
COL1A2 69 collagen, type I, alpha 2
FN1 67 fibronectin 1
MEF2C 61 myocyte enhancer factor 2C
DST 56 dystonin
PALLD 54 palladin, cytoskeletal associated protein
MYH3 52 myosin, heavy chain 3, skeletal muscle, embryonic
MYH8 44 myosin, heavy chain 8, skeletal muscle, perinatal
COL1A1 43 collagen, type I, alpha 1
Table 13: List of top ranked genes in ADM.D4 stage
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2.3 Differential expression analysis
In order to explore the insights of relations between different stages, R package
EdgeR was used to comparing the expressing level of each gene in different stages.Here,
1 times fold change is used to characterize the expression level change, False Discov-
ery Rate(FDR) is used to indicate the reliability of the results. By program default,
| log2 fold| > 1 and FDR < 0.05 was set as threshold. The | log2 fold| represent
the gene differential expressed level between 2 stages, a positive or negative number
means up regulating or down regulating. The default settings of the program would
produce reliable differential expressed genes between stages [10]. Here I have listed
all of the differential expressed genes when other stages are compared to one certain
stage.
15
2.3.1 iPS
stage genes
S1 /
S2 /
S3 COL3A1, COL1A2, COL1A1, MYH3, H19, COL5A2, IGF2, POSTN, COL5A1
ISM.D0 H19
ISM.D4 MYH3, COL3A1, COL1A1, IGF2, TTN, JARID2, PALLD, TNNT2
ADM.D0
FN1, SULF1, RUNX1, COL3A1, PALLD, COL1A2, ADAMTSL1,
COL1A1, COL6A3, ZEB1, ELN, ATP2B1,,ESRG, FBN1, ADAM9,
CBS
ADM.D4
TTN, NEB, MEF2C, MYH3, PALLD, MYH8, COL3A1, POSTN, FN1,
COL1A2, ACTN2, DMD, RUNX1, NCAM1, COL1A1, SGCD,
COL5A2, FBN1, SULF1, DST, ESRG, COL6A2, ARPP21, ZEB1
Table 14: differential expressed genes for iPS stage over other stages
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2.3.2 S1
stage genes
iPS /
S2 /
S3 MYH3, H19, TTN, COL3A1, POSTN, IGF2
ISM.D0 H19
ISM.D4 TTN, MYH3, IGF2
ADM.D0 FN1, TTN, SULF1, RUNX1, ELN
ADM.D4
TTN, NEB, MYH3, MYH8, NCAM1, ACTN2, POSTN, SGCD, DLG2,
MEF2C, F13A1, LDB3, DCLK1, BIN1, LMO7, SULF1, RUNX1, LIN28A,
CADM2, COL6A2, ARPP21, MYH10, SMC4, ITGA7, TNNT2, DST, FN1
Table 15: differential expressed genes for S1 stage over other stages
2.3.3 S2
stage genes
iPS /
S1 /
S3 COL3A1, MYH3, COL1A1, TTN
ISM.D0 /
ISM.D4 TTN, MYH3
ADM.D0 FN1
ADM.D4
TTN, NEB, MEF2C, MYH8, POSTN, MYH3, NCAM1, PALLD, DCLK1,
ACTN2, FN1, SGCD, DLG2, SULF1, LIMCH1,F13A1, LDB3
Table 16: differential expressed genes for S2 stage over other stages
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2.3.4 S3
stage genes
iPS COL3A1, COL1A2, COL1A1, MYH3, H19, COL5A2, IGF2, POSTN, COL5A1
S1 MYH3, H19, TTN, COL3A1, POSTN, IGF2
S2 COL3A1, MYH3, COL1A1, TTN
ISM.D0 MYH3
ISM.D4 /
ADM.D0 MYH3, POSTN
ADM.D4 TTN
Table 17: differential expressed genes for S3 stage over other stages
2.3.5 ISM.D0
stage genes
iPS H19
S1 H19
S2 /
S3 MYH3
ISM.D4 TTN, MYH3
ADM.D0 /
ADM.D4
TTN, NEB, MEF2C, MYH3, NCAM1, MYH8, DCLK1, ACTN2,
POSTN, DMD, DLG2
Table 18: differential expressed genes for ISM.D0 stage over other stages
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2.3.6 ISM.D4
stage genes
iPS MYH3, COL3A1, COL1A1, IGF2, TTN, JARID2, PALLD, TNNT2
S1 TTN, MYH3, IGF2
S2 TTN, MYH3
S3 /
ISM.D0 TTN, MYH3
ADM.D0 MYH3
ADM.D4 /
Table 19: differential expressed genes for ISM.D4 stage over other stages
2.3.7 ADM.D0
stage genes
iPS
FN1, SULF1, RUNX1, COL3A1, PALLD, COL1A2, ADAMTSL1,
COL1A1, COL6A3, ZEB1, ELN, ATP2B1,,ESRG, FBN1, ADAM9,
CBS
S1 FN1, TTN, SULF1, RUNX1, ELN
S2 FN1
S3 MYH3, POSTN
ISM.D0 /
ISM.D4 MYH3
ADM.D4 TTN, MYH3, POSTN, NEB, MYH8
Table 20: differential expressed genes for ADM.D0 stage over other stages
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2.3.8 ADM.D4
stage genes
iPS
TTN, NEB, MEF2C, MYH3, PALLD, MYH8, COL3A1, POSTN, FN1,
COL1A2, ACTN2, DMD, RUNX1, NCAM1, COL1A1, SGCD,
COL5A2, FBN1, SULF1, DST, ESRG, COL6A2, ARPP21, ZEB1
S1
TTN, NEB, MYH3, MYH8, NCAM1, ACTN2, POSTN, SGCD, DLG2,
MEF2C, F13A1, LDB3, DCLK1, BIN1, LMO7, SULF1, RUNX1, LIN28A,
CADM2, COL6A2, ARPP21, MYH10, SMC4, ITGA7, TNNT2, DST, FN1
S2
TTN, NEB, MEF2C, MYH8, POSTN, MYH3, NCAM1, PALLD, DCLK1,
ACTN2, FN1, SGCD, DLG2, SULF1, LIMCH1,F13A1, LDB3
S3 TTN
ISM.D0
TTN, NEB, MEF2C, MYH3, NCAM1, MYH8, DCLK1, ACTN2,
POSTN, DMD, DLG2
ISM.D4 /
ADM.D0 TTN, MYH3, POSTN, NEB, MYH8
Table 21: differential expressed genes for ADM.D4 stage over other stages
From the results, several interesting place can be noticed. iPS, S1, S2 and ISM.D0
have little differential expressed genes. Since ISM.D0 and S2 are all myoblasts, S2 is
developed from S1 and iPS, the result might indicate that HG19 gene distinguishes
ISM cell line from iPS cell line; in iPS and S stages, cells are very similar to ISM
cell line.
iPS cells have significantly more differential expressed genes with later stage cells
then with early stage cells. During the process of differentiation, genes with stage
specific functions will be turned on, thus the differential expressed genes between
iPS stages are potentially connected to certain differentiation function.
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S3, ISM.D4 and ADM.D4 stage have little differential expressed genes. Being
myotubes could explain their little differences. Also S2, ISM.D0, ADM.D0 have
little differential expressed genes could be explained by the same reason. Generally,
a huge difference can be observed between ADM cell line and other cell lines, these
genes are very likely to be related with adult cell differentiation.
The number of differential expressed genes is much smaller than total gene num-
bers in our data, by exploring into the results, I noticed that, most differential
expressed genes are eliminated because of high FDR value. Since the 8 datasets in
our data are all unique ones, lacking of replica might be the reason that the result
has a high FDR value. In further analysis we plan to change the threshold of FDR
value so that we could obtain more gene symbols.
As a conclusion, the gene expression differences in cells from similar tissues(both
myoblasts or myotubes) are less then cells from same cell lines. For example the dif-
ferential expressed genes between ADM.D4 vs ISM.D4 group is more then ADM.D4
vs ADM.D0 group or ISM.D4 vs ISM.D0 group. As the start point of the differen-
tiation process, iPS stage mostly express basic household genes while later stages
would have more stage specific genes expressed. But further analysis also should be
performed, a small number of genes might not tell much about stage wise functions.
2.4 Functional analysis
R package clusterProfiler was used to perform the Gene Ontology(GO) and Kyoto
Encyclopedia of Genes and Genomes(KEGG) pathway analysis. Information for
Molecular Function(the specific activity that gene products play a role in), Cellular
Component(the specific place in a cell where a gene product is located), Biologi-
cal Process(biological activity which a group of genes or gene products participate
in) is obtained using default parameter. Detailed GO information is available in
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supplementary information. Here terms with high gene counts are presented in dot
charts. Top 21 process ranked by gene ratio(number of target gene in term/number
of target gene) are shown in the dot chart. the p value indicated the significance of
enrichment analysis, usually the enrichment is significant when p < 0.05.
2.4.1 Molecular function
(a) (b)
(c) (d)
Figure 6: Gene Ontology analysis in terms of molecular function in each stage.
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(a) (b)
(c) (d)
Figure 7: Gene Ontology analysis in terms of molecular function in each stage.
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2.4.2 Cellular Component
(a) (b)
(c) (d)
Figure 8: Gene Ontology analysis in terms of cellular component in each stage.
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(a) (b)
(c) (d)
Figure 9: Gene Ontology analysis in terms of cellular component in each stage.
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2.4.3 Biological Process
(a) (b)
(c) (d)
Figure 10: Gene Ontology analysis in terms of biological process in each stage.
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(a) (b)
(c) (d)
Figure 11: Gene Ontology analysis in terms of biological process in each stage.
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2.4.4 KEGG analysis
(a) (b)
(c) (d)
Figure 12: Gene Ontology analysis in terms of KEGG pathway in each stage.
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(a) (b)
(c) (d)
Figure 13: Gene Ontology analysis in terms of KEGG pathway in each stage.
The ontology analysis of all genes had included too many functional terms, since
the analysis only concerns about the gene symbol. From previous results I noticed
that for genes with more than 5 transcripts, every stage has expressed their own
features, so I decided to perform a functional analysis in genes with over or equal
to 5 transcripts. The result is listed below.
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2.4.5 Molecular function(over 5 transcripts)
(a) (b)
(c) (d)
Figure 14: Gene Ontology analysis in terms of molecular function in each stage.
30
(a) (b)
(c) (d)
Figure 15: Gene Ontology analysis in terms of molecular function in each stage.
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2.4.6 Cellular Component(over 5 transcripts)
(a) (b)
(c) (d)
Figure 16: Gene Ontology analysis in terms of cellular component in each stage.
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(a) (b)
(c) (d)
Figure 17: Gene Ontology analysis in terms of cellular component in each stage.
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2.4.7 Biological Process(over 5 transcripts)
(a) (b)
(c) (d)
Figure 18: Gene Ontology analysis in terms of biological process in each stage.
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(a) (b)
(c) (d)
Figure 19: Gene Ontology analysis in terms of biological process in each stage.
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2.4.8 KEGG analysis(over 5 transcripts)
(a) (b)
(c) (d)
Figure 20: Gene Ontology analysis in terms of KEGG pathway in each stage.
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(a) (b)
(c) (d)
Figure 21: Gene Ontology analysis in terms of KEGG pathway in each stage.
2.4.9 Stage wise funcitonal analysis
Simply listing all of the results is pretty hard for us to find out the relations under
different stages, according to the differential expressed gene analysis from 2.2, I
have compared gene ontology terms between iPS stage and ADM.D4 stage. Only
3 gene symbols are listed in the table for each term, detailed information can be
found in supplementary information. The terms listed below could be connected to
development of adult myotubes, much differential expressed genes between iPS and
ADM.D4 from 2.2 are also related to these terms.
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ID Term Gene symbol
GO:0048193 Golgi vesicle transport TAPBP/VPS52/CUX1
GO:0006914 autophagy SEC22B/MTM1/MTOR
GO:0061919 process utilizing autophagic mechanism SEC22B/MTM1/MTOR
GO:0034976 response to endoplasmic reticulum stress HSPA1A/FLOT1/UBE2G2
GO:0042176 regulation of protein catabolic process HSPA1A/FLNA/SEC22B
GO:0010256 endomembrane system organization FLOT1/PDE4DIP/TARDBP
GO:0009896 positive regulation of catabolic process HSPA1A/SEC22B/DVL1
GO:0016236 macroautophagy SEC22B/MTM1/MTOR
GO:0016570 histone modification NELFE/RING1/BAZ1B
Table 22: Biological Process for ADM.D4 over iPS
ID Term Gene Symbol
GO:0015629 actin cytoskeleton FLOT1/FLNA/ESPN
GO:0044440 endosomal part HLA-A/HLA-E/HLA-B
GO:0005635 nuclear envelope ABCF1/TUBB/TRIM27
GO:0010008 endosome membrane HLA-A/HLA-E/HLA-B
GO:0005774 vacuolar membrane FLOT1/GNB1/MTOR
GO:0000151 ubiquitin ligase complex HSPA1A/RING1/UBE2J2
GO:0043292 contractile fiber SMN2/FLNA/PDE4DIP
GO:0030016 myofibril SMN2/FLNA/PDE4DIP
GO:0044449 contractile fiber part SMN2/FLNA/MTM1
GO:0030017 sarcomere SMN2/FLNA/MTM1
GO:0042470 melanosome FLOT1/SEC22B/SLC2A1
GO:0048770 pigment granule FLOT1/SEC22B/SLC2A1
Table 23: Cellular Component for ADM.D4 over iPS
ID Term Gene Symbol
GO:0003779 actin binding FLNA/ESPN/KLHL21
GO:0060589 nucleoside-triphosphatase regulator activity DNAJC7/GDI1/SRGAP2B
GO:0051015 actin filament binding FLNA/ESPN/CAPZB
GO:0019902 phosphatase binding PPP1R11/RCAN3/RPA2
GO:0035257 nuclear hormone receptor binding CDK7/ZNHIT3/PADI2
GO:0008135 translation factor activity, RNA binding ABCF1/EIF2D/EIF4G3
GO:0032182 ubiquitin-like protein binding DDI2/FAF1/SPRTN
GO:0003743 translation initiation factor activity EIF2D/EIF4G3/EIF3I
Table 24: Molecular Function for ADM.D4 over iPS
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ID Term
hsa05205 Proteoglycans in cancer
hsa04140 Autophagy - animal
hsa04910 Insulin signaling pathway
hsa04142 Lysosome
hsa04152 AMPK signaling pathway
hsa04722 Neurotrophin signaling pathway
hsa04211 Longevity regulating pathway
hsa04520 Adherens junction
hsa05212 Pancreatic cancer
hsa05220 Chronic myeloid leukemia
hsa05211 Renal cell carcinoma
Table 25: KEGG pathway for ADM.D4 over iPS
2.5 Possible Novel genes and transcripts
Figure 22: unmatched genes and transcripts
According to the description of ToFU pipeline, for each input sequence, NA will be
produced if reference can not be found in reference gene model during the annota-
tion step [8]. Natural we could assume these sequences that can not be matched
to be novel transcripts. The potential novel transcript numbers are produced by:
total transcript numbers−matched transcript numbers, the potential novel gene
numbers are produced by: total gene numbers − matched gene numbers. IGV
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sequence visualization was used to check the authenticity of the novel transcripts
preliminary, several transcripts were visualized and proved to be not overlapping
with any reference genemodel area.
Figure 23: visualization of one novel gene region
Figure 13 is a visualization of 2 reads from iPS stage, c22873/f1p0/596 |GL000220.1 :
132118− 132868(−) and c22883/f1p1/742 | GL000220.1 : 132118− 132868(−). Af-
ter the previous error correction and collapse step, all redundant reads are collapsed
into one unique transcript. Here, 2 reads are 2 transcripts, they are not overlapped
with any transcript or gene with Genecode v19 reference gene model, they are likely
novel transcripts and from a novel gene.
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3 Discussion
3.1 Conclusions
In this study, we characterized the transcriptome information for human skeletal
muscle cell in different stages. The transcripts and alternative splicing events dis-
tribution are investigated across stages. Based on a comprehensive analysis of dif-
ferentiated cells, the expression and functional information obtained in this study
revealed the process of human skeletal muscle cell differentiation. The data will
provide a genomic reference for further skeletal muscle cell differentiation or FSHD
research using iPS cells.
There are also some limitations of our work. The 8 datasets in our data are
all unique ones, which means the features shown in our data could possibly be
coincidences. No replica also brought lots of trouble when I was performing the
gene differential expression analysis, because high FDR value, lots of results were
eliminated.
Also our data are simply collected from healthy people, with no data from pa-
tient we can only explore the gene expression features during skeletal muscle cell
differentiation, while the genes and pathways information related to FSHD can not
be obtained.
And the largest challenge in this study is lacking resource for Iso-Seq analysis.
Iso-Seq is a relatively new technique, it is kind of advanced than other RNA-Seq
techniques in many aspects, which also means we are not able to find many publica-
tions related to Iso-Seq anlysis. Before I was running the analysis following Cupcake
ToFU pipeline, 4 different kinds pipeline had been tried and abandoned, two of them
requires short read sequences(IDP and SpliceGrapher). Pipeline SQANTI can not
even work on their own tutorial data, and pipeline TAPIS contains lots of coding
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error in their python scripts and spent me lots of time fixing the script bugs(the fixed
scripts is available in splimentary information and TAPIS website). When TAPIS
was finally managed to work, I noticed that it would alter the strand information of
the sequence for some unknown reason. These situations all tell that this is a field
that few people are working on.
3.2 Future work
Lacking experimental group is the major limitation of this study. Our sequencing
data are all from healthy people. Without an experimental group, we can only
acquire cell differentiation related information, by comparing healthy data with
patient data we could easily locate genes or pathways underlying FSHD.
More replica could also be used in further study. Since read numbers and gene
numbers can vary from sample to sample due to technique reasons, it is important
to set several replicas to reduce the bias. In our data set, the over 3k part data of S2
stage is dropped because of containing much mitochondrial sequence, this brought
more uncontrolled bias to our analysis. Solutions for such circumstances should be
discussed to ensure to correctness of the analysis.
At last, The analysis revealed the gene expression and gene ontology differences
between stages and cell lines, hypothesis were made based on these results. However,
more biological experiments should be performed to validate the basic results and
hypothesis.
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